Healthcare / Medical DevicesNYSE American
$0.46
+0.00 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-11.0M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$65M
P/E
46.2x
↑EV/EBITDA
5.1x
↓ROE
9.8%
↑Gross Margin
62.9%
↑Debt/Equity
0.56
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
+15.6%
FCF CAGR
—
FCF margin
7.6%
FCF / Net income
2.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $133.9M · net income $5.0M · FCF $10.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $133.9M | $133.9M | $117.3M | $91.3M | $58.0M | $55.3M | $53.3M | $64.7M | $72.2M | $82.6M | $90.0M | $59.3M | $35.3M | $33.1M | $33.0M | $30.1M | $15.2M |
| Net Income | $5.0M | $5.0M | $-16.4M | $660000.00 | $-8.5M | $-4.8M | $-7.0M | $-8.2M | $-70.1M | $-52.4M | $-19.5M | $-2.2M | $-10.5M | $-12.7M | $-7.7M | $-3.0M | $-19.5M |
| EBITDA | $15.9M | $15.9M | $-7.9M | $5.1M | $-5.4M | $-2.5M | $1.3M | $890000.00 | $-53.5M | $-29.4M | $-303394.00 | $-7.2M | $-5.3M | $-8.3M | $-4.2M | $-5.7M | $-7.9M |
| EPS | 0.03 | 0.03 | -0.12 | 0.01 | -0.09 | -0.06 | -0.25 | -0.63 | -5.97 | -34.76 | -18.46 | -2.88 | -21.12 | -33.60 | -21.60 | -9.60 | -73.20 |
| Gross Margin | 62.9% | 62.9% | 58.2% | 60.8% | 55.4% | 58.8% | 64.5% | 65.7% | 60.2% | 60.6% | 69.2% | 65.9% | 63.1% | 57.1% | 68.7% | 69.8% | 79.2% |
| Operating Margin | 5.4% | 5.4% | -10.3% | -11.1% | -11.7% | -7.0% | -1.4% | -3.5% | -83.2% | -45.8% | -8.4% | -20.4% | -17.7% | -27.2% | -15.0% | -21.4% | -56.6% |
| Net Margin | 3.7% | 3.7% | -14.0% | 0.7% | -14.6% | -8.8% | -13.2% | -12.7% | -97.1% | -63.4% | -21.7% | -3.7% | -29.7% | -38.4% | -23.4% | -10.0% | -128.0% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 0.56 | 0.56 | 0.82 | 0.46 | 0.50 | 0.38 | — | -1.72 | -1.78 | -1.14 | -16.85 | 5.04 | -2.68 | -4.26 | 3.42 | 1.21 | -3.54 |
| Current Ratio | 3.34 | 3.34 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $10.2M | $10.2M | $-16.0M | $-11.0M | $-7.1M | $-1.7M | $-2.3M | $-1.3M | $588000.00 | — | — | — | — | — | $-12.6M | $-8.3M | $-9.2M |
| Returns | |||||||||||||||||
| ROE | 9.8% | 9.8% | -38.3% | 1.3% | -24.8% | -15.7% | -48.4% | 18.6% | 160.1% | 89.3% | 275.6% | -24.5% | 135.2% | 330.4% | -182.3% | -54.7% | 3143.8% |
| Valuation | |||||||||||||||||
| P/E | 46.22 | 46.22 | — | 119.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 5.10 | 5.10 | — | 33.25 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 1.36 | 1.36 | 1.65 | 2.94 | 1.73 | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 14.2% | 14.2% | 28.4% | 57.5% | — | 3.6% | -17.5% | -10.4% | -12.6% | -8.2% | 51.7% | 68.0% | 6.8% | 0.3% | 9.4% | 98.2% | — |
| EPS Growth | 125.0% | 125.0% | -1300.0% | 111.1% | — | 76.0% | 60.3% | 89.4% | 82.8% | -88.3% | -541.0% | 86.4% | 37.1% | -55.6% | -125.0% | 86.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
11.0%
EPS terminal req.
$0.04
Spread vs growth
114.0%
5Y implied EPS CAGR
10.6%
EPS terminal req.
$0.05
Spread vs growth
114.4%
10Y implied EPS CAGR
10.3%
EPS terminal req.
$0.08
Spread vs growth
114.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.12 → 0.03
Residual
-30.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.